Admedus to change financial year-end
Admedus Limited (ASX:AHZ) announced that the Company has changed its financial year-end from 30 June to 31 December. This change more closely aligns Admedus’ reporting period with its global business sales cycles, assisting with forecasting, cash flow management and investment decisions. Read the full ASX announcement here.
December 11th 2017Find out more
Admedus announces facility agreement with Partners for Growth
Admedus Ltd today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private and public technology and life science companies. Read full […]
October 26th 2017Find out more
Admedus TAVR project on track with new IP applications
Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.
October 24th 2017Find out more
New neck and head cancer treatment a step closer to trials
As reported widely across Australian media outlets, Admedus Immunotherapies recently received a $250,000 Government grant from the Advance Queensland Ignite Ideas Fund to support human clinical trials, led by Professor Ian Frazer, of a new vaccine that could be used to treat head and neck cancer. Find a copy of the story on News.com, 7 News or Brisbane Times. Read the full […]
October 23rd 2017Find out more
Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products.Learn More